FDA
-
-
-
-
-
-
-
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
-
-
-
-
-
-
-
Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
-
-
-
-
-
-
-
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
-
-
-
-
-
-
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
-
-
-
-
-
-
-
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
-
-
-
-
-
-
-
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
-
-
-
-
-
-
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

